News Category
Moody Capital Solutions will host its 2026 Disruptive Growth & Life Sciences Conference, a two-day event focused on company presentations and schedule...
SuzieQ Holdings Inc. will be featured at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, highlighting its work on quant...
A new study shows that treating certain emergency room patients while seated instead of waiting for a bed can significantly reduce wait times, potenti...
Helus Pharma reports progress in its Phase 3 program for HLP003 in major depressive disorder, with topline data expected in Q4 2026, and provides fina...
Helus Pharma has named Michael Halstead as its new CEO, bringing extensive biopharmaceutical experience as the company advances its lead depression ca...
Ocumetics Technology Corp. has completed the second tranche of its private placement, raising funds to support its first-in-human clinical trials for ...
VERAXA Biotech AG shareholders overwhelmingly approved corporate governance and financing measures at an Extraordinary General Meeting, enabling great...
VERAXA Biotech announced the advancement of its bispecific ADC program VXA-222 after OmniAb completed a key technical milestone, moving the program in...
Gerresheimer has started operations at a new plant in Zhenjiang Dagang, China, doubling its production capacity for primary packaging for injectable p...
Helus Pharma has completed enrollment in its Phase 3 APPROACH trial for HLP003, a deuterated psilocin analogue for major depressive disorder, with res...
Darwin AG has officially changed its name to Novogenia AG, reinforcing its strategic focus on human genetics and personalized healthcare through its s...
NanoViricides reports progress on NV-387, a broad-spectrum oral antiviral candidate for Bundibugyo ebolavirus, with Phase II trial approval pending in...
Redwood AI Corp. has been added to the CSE25 Index, which tracks the 25 largest companies on the Canadian Securities Exchange, potentially increasing ...
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trial for major depressive disorder, with topline data expected in Q4...
Quantum BioPharma is developing Lucid-MS, a drug candidate aimed at repairing myelin damage in multiple sclerosis, as current treatments only slow dis...
Oncotelic Therapeutics' nanoparticle-based drug delivery platform highlights a shift toward improving existing cancer therapies, potentially unlocking...
Quantum BioPharma's Lucid-MS, a first-in-class drug candidate that protects myelin sheath, is preparing for Phase 2 trials after successful Phase 1 st...
VERAXA Biotech announced in vitro proof-of-concept data for its BiTAC-ADC platform, showing selective killing of breast cancer cells while sparing hea...
Redwood AI Corp. is gaining attention as a 'One to Watch' for its AI-powered platforms that aim to speed up chemistry research and development in phar...
New research published in JCI Insight suggests that GeoVax's Gedeptin therapy could enhance immune checkpoint inhibitor responses and activate systemi...
Kairos Pharma announces plans to acquire CL-741, a Phase 1-ready oral c-MET kinase inhibitor, to expand its oncology pipeline, while advancing clinica...
As drug-delivery markets head toward $410 billion, biotech companies like Oncotelic Therapeutics are leveraging platform technologies to enhance exist...
GeoVax Labs' CEO David Dodd comments on recent pharmaceutical acquisitions by Eli Lilly, interpreting them as a strategic shift toward viewing vaccine...
Quantum BioPharma's lead drug candidate Lucid-MS targets mobility loss in multiple sclerosis by addressing nerve damage, while its commercial product ...
Oragenics Inc. reported progress in its Phase IIa trial of ONP-002 for concussion and mild traumatic brain injury in Australia, plans to request a Typ...
Lantern Pharma reported a 47% reduction in R&D spending while advancing key clinical trials and launching its AI drug development platform withZeta.ai...
BioStem Technologies reported first-quarter 2026 net revenue of $6.1 million, with a strategic shift toward hospital markets and progress on Nasdaq up...
Dogwood Therapeutics announced first quarter 2026 financial results, with key pipeline milestones including Phase 2b data for Halneuron® expected this...
Tonix Pharmaceuticals will participate in the RBC Capital Markets Global Healthcare Conference and A.G.P.'s Annual Virtual Healthcare Conference in Ma...
Lantern Pharma (NASDAQ: LTRN) will announce its first-quarter 2026 operating and financial results on May 15, providing updates on clinical trials and...
Kairos Pharma Ltd. announced its virtual annual meeting and disclosed a going concern notice in its 2025 annual report, highlighting financial uncerta...
Annovis Bio CEO Maria Maccecchini will present the company’s multi-protein approach to treating Alzheimer’s disease at Fierce Biotech Week 2026, highl...
BioStem Technologies will release its first quarter 2026 financial results on May 14, 2026, followed by a conference call and webcast at 4:30 PM ET to...
Earth Science Tech Inc. (OTC: ETST) is building a vertically integrated platform combining compounding pharmacy, telemedicine, and clinical services t...
Lexaria Bioscience has extended its Material Transfer Agreement with an undisclosed pharmaceutical company through 2026 to evaluate its DehydraTECH te...
Telomir Pharmaceuticals (NASDAQ: TELO) has closed its acquisition of TELI Pharmaceuticals, securing sole global rights to Telomir-1 (Telomir-Zn) and e...
